LC-MS-based serum metabolomic analysis reveals dysregulation of phosphatidylcholines in esophageal squamous cell carcinoma

Journal of Proteomics

Volumn 127, Issue , 2015, Pages 96-102

  Mir, Sartaj Ahmad ^a,b   Rajagopalan, Pavithra ^a,c   Jain, Ankit P ^a,c   Khan, Aafaque Ahmad ^a,c   Datta, Keshava K ^a,c   Mohan, Sonali V ^a   Lateef, Syed Salman ^d   Sahasrabuddhe, Nandini ^a   Somani, B L ^a   Keshava Prasad, T S ^a   Chatterjee, Aditi ^a   Veerendra Kumar, K V ^e   VijayaKumar, M ^e   Kumar, Rekha V ^e   Gundimeda, Seetaramanjaneyulu ^d   Pandey, Akhilesh ^f   Gowda, Harsha ^a  

^a INSTITUTE OF BIOINFORMATICS   (India)

^b MANIPAL UNIVERSITY   (India)

^c KIIT UNIVERSITY   (India)

^d Agilent Technologies Ltd   (India)

^e KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cholines; Lyso PCs; Metabolism; PCs; Serum metabolome

Indexed keywords

PHOSPHATIDYLCHOLINE;

ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; ADULT; BLOOD; ESOPHAGUS TUMOR; FEMALE; MALE; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

ADULT; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; PHOSPHATIDYLCHOLINES;

EID: 84943198386     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.05.013     Document Type: Article

References (42)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336:1040-1044.
3. Budczies J., Brockmoller S.F., Muller B.M., Barupal D.K., Richter-Ehrenstein C., Kleine-Tebbe A., et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J. Proteome 2013, 94C:279-288.
4. Qiu Y., Cai G., Su M., Chen T., Zheng X., Xu Y., et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J. Proteome Res. 2009, 8:4844-4850.
5. Urayama S., Zou W., Brooks K., Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun. Mass Spectrom. 2010, 24:613-620.
6. Xiao J.F., Varghese R.S., Zhou B., Nezami Ranjbar M.R., Zhao Y., Tsai T.H., et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J. Proteome Res. 2012, 11:5914-5923.
7. Wang B., Chen D., Chen Y., Hu Z., Cao M., Xie Q., et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J. Proteome Res. 2012, 11:1217-1227.
8. Chen T., Xie G., Wang X., Fan J., Qiu Y., Zheng X., et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol. Cell. Proteomics 2011, 10. (M110 004945).
9. Zhang T., Wu X., Ke C., Yin M., Li Z., Fan L., et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J. Proteome Res. 2013, 12:505-512.
10. Lin L., Huang Z., Gao Y., Yan X., Xing J., Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. J. Proteome Res. 2011, 10:1396-1405.
11. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
12. Kind T., Tolstikov V., Fiehn O., Weiss R.H. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal. Biochem. 2007, 363:185-195.
13. Kim K., Taylor S.L., Ganti S., Guo L., Osier M.V., Weiss R.H. Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS 2011, 15:293-303.
14. Ganti S., Taylor S.L., Kim K., Hoppel C.L., Guo L., Yang J., et al. Urinary acylcarnitines are altered in human kidney cancer. Int. J. Cancer 2012, 130:2791-2800.
15. Xu J., Chen Y., Zhang R., Song Y., Cao J., Bi N., et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol. Cell. Proteomics 2013, 12:1306-1318.
16. Zhang A., Sun H., Wang P., Han Y., Wang X. Modern analytical techniques in metabolomics analysis. Analyst 2012, 137:293-300.
17. Gika H.G., Theodoridis G.A., Plumb R.S., Wilson I.D. Current practice of liquid chromatography-mass spectrometry in metabolomics and metabonomics. J. Pharm. Biomed. Anal. 2014, 87:12-25.
18. Metz T.O., Zhang Q., Page J.S., Shen Y., Callister S.J., Jacobs J.M., et al. The future of liquid chromatography-mass spectrometry (LC-MS) in metabolic profiling and metabolomic studies for biomarker discovery. Biomark. Med 2007, 1:159-185.
19. Wang L., Chen J., Chen L., Deng P., Bu Q., Xiang P., et al. 1H-NMR based metabonomic profiling of human esophageal cancer tissue. Mol. Cancer 2013, 12:25.
20. Zhang X., Xu L., Shen J., Cao B., Cheng T., Zhao T., et al. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. Biochim. Biophys. Acta 1832, 2013:1207-1216.
21. Wu H., Xue R., Lu C., Deng C., Liu T., Zeng H., et al. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:3111-3117.
22. Ikeda A., Nishiumi S., Shinohara M., Yoshie T., Hatano N., Okuno T., et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed. Chromatogr. 2012, 26:548-558.
23. Sana T.R., Gordon D.B., Fischer S.M., Tichy S.E., Kitagawa N., Lai C., et al. Global mass spectrometry based metabolomics profiling of erythrocytes infected with Plasmodium falciparum. PLoS One 2013, 8:e60840.
24. Wishart D.S., Jewison T., Guo A.C., Wilson M., Knox C., Liu Y., et al. HMDB 3.0-the human metabolome database in 2013. Nucleic Acids Res. 2013, 41:D801-D807.
25. Fahy E., Subramaniam S., Murphy R.C., Nishijima M., Raetz C.R., Shimizu T., et al. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009, 50(Suppl.):S9-S14.
26. Tautenhahn R., Cho K., Uritboonthai W., Zhu Z., Patti G.J., Siuzdak G. An accelerated workflow for untargeted metabolomics using the METLIN database. Nat. Biotechnol. 2012, 30:826-828.
27. Pacetti D., Boselli E., Hulan H.W., Frega N.G. High performance liquid chromatography-tandem mass spectrometry of phospholipid molecular species in eggs from hens fed diets enriched in seal blubber oil. J. Chromatogr. A 2005, 1097:66-73.
28. Hsu F.F., Turk J., Thukkani A.K., Messner M.C., Wildsmith K.R., Ford D.A. Characterization of alkylacyl, alk-1-enylacyl and lyso subclasses of glycerophosphocholine by tandem quadrupole mass spectrometry with electrospray ionization. J. Mass Spectrom. 2003, 38:752-763.
29. Kuhajda F.P., Jenner K., Wood F.D., Hennigar R.A., Jacobs L.B., Dick J.D., et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:6379-6383.
30. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
31. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
32. Zhang F., Du G. Dysregulated lipid metabolism in cancer. World J. Biol. Chem. 2012, 3:167-174.
33. Rysman E., Brusselmans K., Scheys K., Timmermans L., Derua R., Munck S., et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 2010, 70:8117-8126.
34. Iorio E., Ricci A., Bagnoli M., Pisanu M.E., Castellano G., Di Vito M., et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010, 70:2126-2135.
35. Ramirez de Molina A., Gutierrez R., Ramos M.A., Silva J.M., Silva J., Bonilla F., et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002, 21:4317-4322.
36. Eliyahu G., Kreizman T., Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer 2007, 120:1721-1730.
37. Iorio E., Mezzanzanica D., Alberti P., Spadaro F., Ramoni C., D'Ascenzo S., et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005, 65:9369-9376.
38. Nakagami K., Uchida T., Ohwada S., Koibuchi Y., Suda Y., Sekine T., et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res. 1999, 90:419-424.
39. Katz-Brull R., Seger D., Rivenson-Segal D., Rushkin E., Degani H. Metabolomic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002, 62:1966-1970.
40. Tennant D.A., Duran R.V., Gottlieb E. Targeting metabolomic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
41. Liu R., Peng Y., Li X., Wang Y., Pan E., Guo W., et al. Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform. Int. J. Mol. Sci. 2013, 14:8899-8911.
42. Brites P., Waterham H.R., Wanders R.J. Functions and biosynthesis of plasmalogens in health and disease. Biochim. Biophys. Acta 2004, 1636:219-231.